BSV developed the World’s 1st recombinant Anti Rh(o)-D Immunoglobin

Trinbelimab (recombinant Anti Rh(o) D Immunogloblin) is used in the prevention of Rh isoimmunization by preventing the Rh-negative mother forming antibodies towards her Rh-positive fetus red blood cells that may pass into the maternal blood during childbirth, abortion, or certain other sensitizing events.

BSV is a leading supplier of Trinbelimab (recombinant Anti Rh(o) D immunoglobulin) for postpartum prophylaxis of un-sensitized Rh-negative women to prevent isoimmunization by red blood cells from Rh-positive fetus.  Trinbelimab (recombinant Anti Rh(o) D immunoglobulin) administration has significantly helped in preventing hemolytic disease in newborns (HDN) by providing a reliable supply of Trinbelimab (recombinant Anti Rh(o) D immunoglobulin) in India for over 35 years. 

  • New biological entity from India with worldwide patent
  • The only ‘mid-sized’ company to develop an innovative ‘New Biological Entity (NBE) – Monoclonal Anti D (Rhoclone) Immunoglobulins
  • Serum free growth medium
  • Trinbelimab (recombinant Anti Rh(o) D immunoglobulin) is an example of pioneering new technologies from India in line with “Atmanirbharta”
  • Trinbelimab (recombinant Anti Rh(o) D immunoglobulin) was launched in 2021
  • World’s 1st marketed recombinant Anti Rh(o) D immunoglobulin

Story of AntiD by BSV